Clinical Trial Update: Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating nab-paclitaxel in combination with pyrotinib as postoperative adjuvant therapy for HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Early Breast Cancer | Phase 2 | Status: UNKNOWN